z-logo
Premium
Intragraft cytokine expressionf in tolerant rat renal allografts with rapamycin and cyclosporin immunosuppression
Author(s) -
Saggi Bh,
Fisher Ra,
Naar Jd,
Bu D,
Obias V,
Tawes Jw,
Wakely Jr Paul E,
Posner Mp
Publication year - 1999
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.1999.130105.x
Subject(s) - immunosuppression , medicine , transplantation , kidney , immune tolerance , cytokine , immunology , kidney transplantation , mixed lymphocyte reaction , t cell , immune system
The Th‐1/Th‐2 paradigm proposes clonal expansion of Th‐2 lymphocytes as the basis of tolerance towards allografts. Intragraft cytokine expression was evaluated in a highly stringent model of renal transplantation. ACI and Lewis rats were used as donors and recipients, respectively, for heterotopic renal transplantation. Group A (n=8) received a single dose of rapamycin and cyclosporin 12 h prior to engraftment, followed by 7 d of cyclosporin post‐operatively. Isografts (Group B, n=5) and control allografts (Group C, n=4) received no immunosuppression. Sacrifice was performed after 120 d. Intragraft expression of IL‐10, IL‐4, and IFN‐ Γ was determined using qualitative reverse transcriptase‐polymerase chain reaction (RT‐PCR). All groups had functionally normal grafts at sacrifice, with 50% histological tolerance among Group A animals. No isografts showed evidence of cellular infiltrate, and all control allografts showed severe rejection. IL‐10 was only detected in the tolerant animals (p<0.001). Similarly, IL‐4 was detected predominantly in the tolerant allografts (p<0.05). IFN‐ Γ was only isolated in rejected allografts, whether treated or untreated (p<0.001). We conclude that the expansion of Th‐2 cells is associated with tolerance, while the expansion of Th‐1 cells is associated with acute cellular rejection.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here